Released Nov 5, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001193125-25-267453
Q3 2025 · 10-Q
Revenue$278.63M$278.63M +11.3% vs Q3 2024+5.3% vs Q2 2025
Net Income$71.78M$71.78M +119.1% vs Q3 2024+169.2% vs Q2 2025
EPS Diluted$0.42$0.42 +110.0% vs Q3 2024+162.5% vs Q2 2025
Operating Income$35,756,000+13.0%
Operating Cash Flowderived$74,288,000+17.5%
Free Cash Flowderived$73,900,000+17.0%
Margins · derived
Operating margin12.8%+0.2 pt vs Q3 2024
Net margin25.8%+12.7 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $278.63M | $250.40M | $211.70M | $130.71M |
| Net Income | $71.78M | $32.77M | -$65.18M | -$27.18M |
| EPS Diluted | $0.42 | $0.20 | -$0.40 | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR